Rosa PK/PD Collaboration with Pfizer to be Presented at ASCPT 2012

PK/PD analyses used to support the rationale for therapeutic strategies targeting myostatin pathway
 
 
Spread the Word
Listed Under

Tags:
PK/PD
Drug-disease Modeling
Pharmacokinetics
PK models
Pharmacodynamics
Muscle-wasting
Muscular Dystrophy
Cachexia

Industrys:
Medical
Science
Research

Location:
San Carlos - California - US

March 8, 2012 - PRLog -- Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that results from its PK/PD collaboration with Pfizer will be presented as a poster at the 2012 American Society for Clinical Pharmacology and Therapeutics annual meeting in National Harbor, Maryland. The poster entitled "Role of Myostatin Pathway in Muscle Growth: Key Learnings from Retrospective Analysis of MYO-029 Preclinical and Clinical Data Thru PK/PD Modeling" will be presented March 17, 2012. The poster describes PK/PD and other analysis of ACE-031, an Fc fusion of ActRIIB decoy receptor of myostatin in animal species and humans, and describes the positive impact the analysis has had in guiding further development.

"We are pleased to have Pfizer present these results from our collaboration. This work clearly demonstrates the importance and impact of incorporating pharmacometrics and modeling into the drug development process," said Dr. Toufigh Gordi, President, PK/PD and Clinical Pharmacology Services

About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit http://www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

# # #

Rosa creates robust mathematical models that simulate drug effects and trial outcomes. Modeling and Simulation complement traditional experimental methods, enabling unique insights that streamline drug development and regulatory interactions.
End
Rosa & Co PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share